Horváth M, Varsányi M, Jovanovich N, Rózsás Z, Balázsi I
3rd Department of Medicine, Semmelweis Medical University, Budapest, Hungary.
Exp Clin Endocrinol. 1987 Aug;89(3):354-62. doi: 10.1055/s-0029-1210662.
Since several data refer to the role of immune processes in the pathogenesis of diabetes mellitus, this study was performed to compare aspecific and specific immune reactions in type I- and in type II diabetic patients over a six month period. The percentage and the absolute number of SRBC-rosette forming active E(A), of theophylline-resistant E(Thr) and of ORCB-rosette forming T(M)-cell subsets proved to be elevated in newly diagnosed type I but reduced in type II diabetic patients. Also an elevated percentage of HLA-DR positive, activated T cells was found in the majority of recent-onset type I diabetics. In the presence of human pancreas extract, a significant inhibition of leucocyte migration, a pronounced and specific cytotoxic capacity of all lymphocyte subsets (especially of the T(G)-cells), and elevated antibody titers (passive haemagglutination, indirect immunofluorescence) were observed in almost all type I diabetics, but only in a few cases of type II patients. After six months, the frequency both of the aspecific and of the specific immune parameters was decreased in type I diabetics, but no changes were observed in the type II diabetics with a previously positive test. The latter patients required insulin therapy at the time of the second investigation. The leucocyte migration inhibition test and the lymphocyte-mediated cytotoxicity are suitable for studying in-vitro-sensitization against pancreatic tissue and they might predict later insulin-dependency in type II diabetic patients.
由于多项数据表明免疫过程在糖尿病发病机制中发挥作用，本研究旨在比较 I 型和 II 型糖尿病患者在六个月期间的非特异性和特异性免疫反应。结果显示，新诊断的 I 型糖尿病患者中，形成 SRBC 玫瑰花结的活性 E(A)细胞、对茶碱耐药的 E(Thr)细胞以及形成 ORCB 玫瑰花结的 T(M)细胞亚群的百分比和绝对数量均升高，而 II 型糖尿病患者中这些指标则降低。此外，大多数新发病的 I 型糖尿病患者中 HLA-DR 阳性活化 T 细胞的百分比也升高。在人胰腺提取物存在的情况下，几乎所有 I 型糖尿病患者均观察到白细胞迁移显著抑制、所有淋巴细胞亚群（尤其是 T(G)细胞）具有明显的特异性细胞毒性能力以及抗体滴度升高（被动血凝、间接免疫荧光），而 II 型患者仅在少数病例中出现上述情况。六个月后，I 型糖尿病患者的非特异性和特异性免疫参数频率均降低，但先前检测呈阳性的 II 型糖尿病患者未观察到变化。第二次调查时，后一组患者需要胰岛素治疗。白细胞迁移抑制试验和淋巴细胞介导的细胞毒性适用于研究针对胰腺组织的体外致敏情况，并且可能预测 II 型糖尿病患者未来是否依赖胰岛素。
